NSE: AUROPHARMA | BSE: 524804

Value Stock, Under Radar

Download real time

1138.70 -5.10 (-0.45%)

28.47% Fall from 52W High

1.1M NSE+BSE Volume

NSE 04 Jun, 2025 3:31 PM (IST)

66,135.9

Market Cap

High in industry

0.9

Beta 1Year

Low volatility

Aurobindo Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for AUROPHARMA, BSE:524804 Aurobindo Pharma Ltd.

Aurobindo Pharma Ltd.

08 Aug 2019

1138.70

-0.45%

Aurobindo Pharma Limited

Buy: Aurobindo Pharma Ltd.

Target

ICICI Securities Limited

US key growth driver; acquisitions to strengthen US basket After filing ANDA in the US in 2003, the company has come a long way as current ANDA filings are at 551. US revenues have grown from ~US$100 million in 2009 crossing $1 billion sales as on 2017. In rupee terms, US sales have grown at 17% CAGR to | 9031 crore in FY15-19. US formulations now constitute 46% of total turnover, up from 30% in FY13. Post acquisition of Sandoz' US dermatology and oral solid businesses, Aurobindo will become the second largest generic player in the US by number of prescriptions. Due...

Number of FII/FPI investors decreased from 730 to 724 in Mar 2025 qtr

Aurobindo Pharma Ltd.

08 Aug 2019

1138.70

-0.45%

Q1FY20 Result Update

Buy: Aurobindo Pharma Ltd.

Target

Prabhudas Lilladhar

The Q1FY20 sales, adj. EBITDA and PAT beat our estimates by 7%, 9% and Change in Estimates | Target | Reco 2% respectively. While the injectable business was in line with guidance, its flat growth with sales of US$67m in US injectable, despite seasonal...

Axis Direct released a Buy report for Aurobindo Pharma Ltd. with a price target of 1500.0 on 28 May, 2025.

Aurobindo Pharma Ltd.

08 Aug 2019

1138.70

-0.45%

Aurobindo Pharma (BUY): Good beat; progress on facility issues & Sandoz are key catalysts

Buy: Aurobindo Pharma Ltd.

Target

BOB Capital Markets Ltd.

Q1FY20 revenue/EBITDA beat estimates by 8%/10% spurred by strong US sales at US$ 384mn and 260bps gross margin expansion YoY and QoQ.

Aurobindo Pharma Ltd. is trading below all available SMAs

Aurobindo Pharma Ltd.

03 Jul 2019, 12:00AM

1138.70

-0.45%

Robust comprehensive plan key to resolve regulatory headwind

Buy: Aurobindo Pharma Ltd.

Target

Motilal Oswal

The WL highlighted that the company has initiated recalls/additional process controls and testing of all manufactured batches of certain API, post the mention by regulatory agencies. There has been failure to ensure that equipment surface in contact with the API does not alter it beyond the established specification. Though the company has engaged a consultant to evaluate operations, the WL highlighted that the firms management will be responsible for fully resolving all deficiencies to ensure CGMP compliance. The WL also indicated that the USFDA has cited similar CGMP observations at other sites Unit I and Unit IX. the USFDA would require comprehensive measures to ensure adequate quality oversight of operations/equipment that could affect the drug quality, including any revised qualification and evaluation procedures. The USFDA would also require an update on the CAPA plans already initiated by ARBP, in addition to a thorough review of all API batches made at ARBP sites, in terms of impurities above reported thresholds.

Promoters unpledged 0.91% of shares in last quarter. Total pledge stands at 16.92% of promoter holdings

Aurobindo Pharma Ltd.

28 Jun 2019

1138.70

-0.45%

Aurobindo Pharm

Hold: Aurobindo Pharma Ltd.

Sharekhan

A Warning Letter has been issued to Aurobindo Pharma Limited (Aurobindo) for its Unit-XI, an Active Pharmaceutical Ingredient (API) unit in Srikakulam, one of the three plants that received Official Action Indicated (OAI) status in May 2019. The letter mainly pertains to the ongoing issues regarding impurities in Sartan's. The company proposes to enter into dialogue with the US FDA over the next 1520 days to decide a future course of action. From Unit XI, the company...

Number of FII/FPI investors decreased from 730 to 724 in Mar 2025 qtr

Aurobindo Pharma Ltd.

21 Jun 2019

1138.70

-0.45%

Aurobindo Pharma Limited

Buy: Aurobindo Pharma Ltd.

Target

ICICI Securities Limited

Aurobindo Pharma has received a warning letter from the USFDA for Unit XI, API manufacturing facility in Srikakulam district, Andhra Pradesh. This action follows the earlier inspection of the site by the USFDA and issuance of Form 483 with three observations in February 2019. Post inspection, USFDA had classified this plant as Official Action Indicated (OAI). Apart from Unit XI, the company has OAI status on Unit I (API facility) and Unit IX (Intermediate facility). Unit XI is the largest API plant of the company followed by Unit I. According to the management, there are just ~15...

Axis Direct released a Buy report for Aurobindo Pharma Ltd. with a price target of 1500.0 on 28 May, 2025.

Aurobindo Pharma Ltd.

03 Jun 2019, 12:00AM

1138.70

-0.45%

Aurobindo Pharma Ltd. - Result Update - 30 May 2019

Results Update: Aurobindo Pharma Ltd.

Way2Wealth

Aurobindo Pharma's revenue grew 31% on a YoY basis to `5292 crs. in Q4. Growth was led by all business segments with the US and growth markets reporting sharp growth of 43% and 38% respectively on a YoY basis. Consolidated EBITDA increased to `1,060 Cr vs. `804 Cr in Q4 last year, an increase of...

Number of FII/FPI investors decreased from 730 to 724 in Mar 2025 qtr

Aurobindo Pharma Ltd.

29 May 2019

1138.70

-0.45%

Aurobindo Pharma (4QFY19): Regulatory concerns misplaced. Upgrade to BUY

Buy: Aurobindo Pharma Ltd.

Recommendation

HDFC Securities

Having fallen 18-20% over the trailing month on regulatory concerns related to three API/intermediate plants, the stock is now available at 14x FY20E EPS, a ~15% discount to its five-year historical average. We believe the concerns are misplaced as only 5-6 products (out of 100+ pending) are dependent on these plants. With high visibility on FY21E EPS of Rs 53.2 driven by the Sandoz acquisition, we see this as a good entry point for investors and expect at least ~15% upside in the near term as this acquisition materializes. Upgrade to BUY. We upgrade ARBP to BUY owing to attractive valuations after the recent fall in stock price. Our TP at Rs 800 is unchanged (15x FY21E EPS).

Number of FII/FPI investors decreased from 730 to 724 in Mar 2025 qtr

Aurobindo Pharma Ltd.

29 May 2019

1138.70

-0.45%

Aurobindo Pharma (BUY): Progress on OAI and Sandoz integration key stock catalysts

Buy: Aurobindo Pharma Ltd.

BOB Capital Markets Ltd.

Progress on OAI and Sandoz integration key stock catalysts Aurobindo Pharma (ARBP) saw soft operating leverage in Q4 despite best-ever US sales at US$ 352mn, partly led by Spectrum integration and higher injectable sales. Revenue/EBITDA beat estimates by 8%/13% but gross margins at 55.2% saw moderate expansion QoQ (provisioning for Valsartan recall). Management is fairly confident about FY20 growth and expects Sandoz FTC approvals by Jul'19 end. We retain our FY20/FY21 EPS of Rs 49/Rs 52. Sandoz integration...

Aurobindo Pharma Ltd. has an average target of 1493.80 from 10 brokers.

Aurobindo Pharma Ltd.

29 May 2019

1138.70

-0.45%

Aurobindo Pharma Limited

Buy: Aurobindo Pharma Ltd.

Target

ICICI Securities Limited

US key growth driver; acquisitions to strengthen US basket After filing ANDA in the US in 2003, the company has come a long way as current ANDA filings are at 541. US revenues have grown from ~US$100 million in 2009 crossing $1 billion sales as on 2017. In rupee terms, US sales have grown at 17% CAGR to | 9031 crore in FY15-19. US formulations now constitute 46% of total turnover, up from 30% in FY13. Post acquisition of Sandoz' US dermatology and oral solid businesses, Aurobindo will become the second largest generic player in the US by number of prescriptions. Due...

Promoters unpledged 0.91% of shares in last quarter. Total pledge stands at 16.92% of promoter holdings

Is Aurobindo Pharma Ltd. worth buying?

1244 Votes:

Buy 80.14%

Sell 13.83%

Hold 6.03%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf